Design and Synthesis of Potent, Selective Inhibitors of Matriptase
ACS Medicinal Chemistry Letters2012Vol. 3(7), pp. 530–534
Citations Over TimeTop 11% of 2012 papers
Éloïc Colombo, Antoine Désilets, Dominic Duchêne, Félix Chagnon, Rafaël Najmanovich, Richard Leduc, Éric Marsault
Abstract
Matriptase is a member of the type II transmembrane serine protease family. Several studies have reported deregulated matriptase expression in several types of epithelial cancers, suggesting that matriptase constitutes a potential target for cancer therapy. We report herein a new series of slow, tight-binding inhibitors of matriptase, which mimic the P1-P4 substrate recognition sequence of the enzyme. Preliminary structure-activity relationships indicate that this benzothiazole-containing RQAR-peptidomimetic is a very potent inhibitor and possesses a good selectivity for matriptase versus other serine proteases. A molecular model was generated to elucidate the key contacts between inhibitor 1 and matriptase.
Related Papers
- → Plant serine proteases: biochemical, physiological and molecular features(2005)187 cited
- → Covalent activity-based probes for imaging of serine proteases(2024)1 cited
- → Serine proteases: how did chemists tease out their catalytic mechanism?(2019)15 cited
- → Chapter 1 Serine proteases: classification, catalytic mechanism, types, and industrial applications(2023)2 cited
- → Serine Proteases and Serine Protease Inhibitors(2008)7 cited